Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.

Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schömig A, Kastrati A, Sibbing D.

Am Heart J. 2011 Mar;161(3):605-10. doi: 10.1016/j.ahj.2010.11.010. Epub 2011 Jan 31.

PMID:
21392618
2.

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.

3.

Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.

Schulz S, Sibbing D, Braun S, Morath T, Mehilli J, Massberg S, Byrne RA, Schömig A, Kastrati A.

Am Heart J. 2010 Aug;160(2):355-61. doi: 10.1016/j.ahj.2010.05.003.

PMID:
20691843
4.

Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.

Gremmel T, Durstberger M, Eichelberger B, Koppensteiner R, Panzer S.

Cardiovasc Ther. 2015 Oct;33(5):264-9. doi: 10.1111/1755-5922.12138.

PMID:
26014752
5.

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2009 Apr;101(4):714-9.

PMID:
19350116
6.

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Heart. 2010 Feb;96(3):186-9. doi: 10.1136/hrt.2009.171488. Epub 2009 Aug 16.

PMID:
19687016
7.

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, Ruven HJ, Klungel OH, de Boer A, Deneer VH.

Thromb Haemost. 2010 May;103(5):920-5. doi: 10.1160/TH09-08-0516. Epub 2010 Mar 29.

PMID:
20352154
8.

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.

Siller-Matula JM, Lang I, Christ G, Jilma B.

J Am Coll Cardiol. 2008 Nov 4;52(19):1557-63. doi: 10.1016/j.jacc.2008.07.055.

9.

High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.

Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, Cerisano G, Carrabba N, Gensini GF, Abbate R, Antoniucci D.

Circulation. 2009 Dec 1;120(22):2214-21. doi: 10.1161/CIRCULATIONAHA.109.883454. Epub 2009 Nov 16.

10.

Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.

Migliorini A, Valenti R, Parodi G, Marcucci R, Abbate R, Carrabba N, Gensini GF, Antoniucci D.

Am J Cardiol. 2013 Dec 15;112(12):1843-8. doi: 10.1016/j.amjcard.2013.08.009. Epub 2013 Sep 21.

PMID:
24063827
11.

Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.

Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group.

J Cardiovasc Pharmacol. 2015 Oct;66(4):364-70. doi: 10.1097/FJC.0000000000000288.

PMID:
26065844
12.

High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.

Leé S, Vargová K, Hizoh I, Horváth Z, Gulácsi-Bárdos P, Sztupinszki Z, Apró A, Kovács A, Préda I, Tóth-Zsámboki E, Kiss RG.

Thromb Res. 2014 Feb;133(2):257-64. doi: 10.1016/j.thromres.2013.11.029. Epub 2013 Dec 6.

PMID:
24359966
13.

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D.

J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7. Epub 2007 Jun 4.

14.

Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.

Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2010 Jan;103(1):151-9. doi: 10.1160/TH09-05-0284. Epub 2009 Oct 26.

PMID:
20062919
15.

Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).

Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue ML.

JACC Cardiovasc Interv. 2013 Dec;6(12):1275-81. doi: 10.1016/j.jcin.2013.06.014. Epub 2013 Nov 13.

16.

A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.

Wenaweser P, Eshtehardi P, Abrecht L, Zwahlen M, Schmidlin K, Windecker S, Meier B, Haeberli A, Hess OM.

Thromb Haemost. 2010 Sep;104(3):554-62. doi: 10.1160/TH09-11-0765. Epub 2010 Jul 20.

PMID:
20664903
17.

Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.

Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, ten Berg JM, Klungel OH, de Boer A, Deneer VH.

J Thromb Haemost. 2011 Oct;9(10):1892-901. doi: 10.1111/j.1538-7836.2011.04483.x.

18.

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators.

JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290. Erratum in: JAMA. 2011 Jun 1;305(21);2174. Stillablower, Michael E [corrected to Stillabower, Michael E].

PMID:
21406646
19.

Association of the use of amlodipine with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention.

Liu XQ, Lin S, Qiu LL, Lin L, Zhao YY, Xu HM, Zhang J, Zou JJ.

Pharmazie. 2014 Nov;69(11):814-7.

PMID:
25985576
20.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A.

J Thromb Haemost. 2010 Feb;8(2):250-6. doi: 10.1111/j.1538-7836.2009.03709.x. Epub 2009 Nov 28.

Supplemental Content

Support Center